Home » Almonds keep arteries healthy.

Almonds keep arteries healthy.

Almonds keep arteries healthy, reduce risk of heart disease Scientists have discovered that eating almonds in what you eat can reduce the risk of cardiovascular disease by keeping arteries healthy. Research discovered that they significantly increase the amount of antioxidants in the bloodstream, reduce blood pressure and improve blood circulation. These findings add excess weight to the idea that Mediterranean diet programs with plenty of nuts have big health benefits. The study was led by Professor Helen Griffiths, Professor in Biomedical Sciences and Executive Dean of the institution of Life and Wellness Sciences at Aston University in Birmingham, UK.

National Tumor Institute. Non-small cell lung cancer may be the most common type of lung cancer.

3SBio obtains ex-China global rights to Apexigen’s anti-TNF mAb technology 3SBio Inc., , a respected China-based biotechnology company centered on researching, developing, marketing and manufacturing biopharmaceutical items, today announced that it offers acquired the ex-China global privileges to Apexigen's anti-TNF monoclonal antibody technology. 3SBio previously acquired the China rights from Apexigen in 2006. 3SBio's anti-TNF mAb, designated SSS07, has completed pre-clinical testing and demonstrated higher potency compared to the best-known available TNF inhibitors, including infliximab and adalimumab, potentially improving treatment plans for patients with arthritis rheumatoid and other inflammatory illnesses.National Tumor Institute. Non-small cell lung cancer may be the most common type of lung cancer.

3SBio obtains ex-China global rights to Apexigen’s anti-TNF mAb technology 3SBio Inc., , a respected China-based biotechnology company centered on researching, developing, marketing and manufacturing biopharmaceutical items, today announced that it offers acquired the ex-China global privileges to Apexigen's anti-TNF monoclonal antibody technology. 3SBio previously acquired the China rights from Apexigen in 2006. 3SBio's anti-TNF mAb, designated SSS07, has completed pre-clinical testing and demonstrated higher potency compared to the best-known available TNF inhibitors, including infliximab and adalimumab, potentially improving treatment plans for patients with arthritis rheumatoid and other inflammatory illnesses.